Objectives Liver kinase B1 (LKB1) is considered a tumour suppressor that can control cell growth and metabolism. Whether LKB1 expression levels are related to clinicopathology and prognosis is controversial. This review aimed to quantitatively examine the latest evidence on this question. Design An updated systematic review and metaanalysis on the association between LKB1 expression and prognosis of patients with solid tumours were performed. Data sources Eligible studies were identified through literature searches from database establishment until 15 June 2018 in the following databases: Embase, PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure and Wan Fang databases. Eligibility criteria The association between LKB1 expression and clinicopathological characteristics, overall survival (OS), disease-free survival (DFS) and relapsefree survival (RFS) of patients with solid tumours were reported. Sufficient data were available to calculate the OR or HR and 95% CI. Data extraction and synthesis Relevant data were meta-analysed for OS, DFS, RFS and various clinical parameters. results The systematic review included 25 studies containing 6012 patients with solid tumours. Compared with patients with high LKB1 expression, patients with low expression showed significantly shorter OS in univariate analysis (HR=1.63, 95% CI 1.35 to 1.97, p<0.01) and multivariate analysis (HR=1.61, 95% CI 1.26 to 2.06, p<0.01). In contrast, the two groups showed similar DFS in univariate analysis (HR=1.49, 95% CI 0.73 to 3.01, p=0.27) as well as similar RFS in univariate analysis (HR=1.44, 95% CI 0.65 to 3.17, p=0.37) and multivariate analysis (HR=1.02, 95% CI 0.42 to 2.47, p=0.97). Patients with low LKB1 expression showed significantly worse tumour differentiation (OR=1.71, 95% CI 1.14 to 2.55, p<0.01), larger tumours (OR=1.68, 95% CI 1.24 to 2.27, p<0.01), earlier lymph node metastasis (OR=1.43, 95% CI 1.26 to 1.62, p<0.01) and more advanced tumour, node, metastases (TNM) stage (OR=1.80, 95% CI 1.56 to 2.07, p<0.01). Conclusion Low LKB1 expression predicts shorter OS, worse tumour differentiation, larger tumours, earlier lymph node metastasis and more advanced TNM stage.
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Low LKB1 expression may be a useful biomarker of poor clinicopathology and prognosis.
IntrODuCtIOn
The serine/threonine kinase liver kinase B1 (LKB1), also known as STK11, was originally observed to be mutated in the genes of patients with Peutz-Jeghers syndrome.
1 LKB1 is often mutated in lung, breast, gastric and other cancers. [2] [3] [4] LKB1 plays key roles in multiple cellular processes, including cell structure control, cell cycle regulation, apoptosis and cellular metabolism. [5] [6] [7] LKB1 phosphorylates multiple substrates, including AMPK, to act as a tumour suppressor to restrict tumourigenesis and metastasis. 8 Mice with a regulatory T cell (Treg)-specific deletion of LKB1 develop a fatal inflammatory disease, and LKB1 in Treg cells acts not through signalling by AMPK or the mammalian target of rapamycin complex 1 (mTORC1) and hypoxia-inducible factor 1, but through signalling involving programmed cell death protein 1 and TNF receptor proteins.
9 LKB1 deficiency can render tumour cells sensitive to metabolic stress, which may turn out to be an antitumour strategy. 10 Although several studies have examined the role of LKB1 in tumour inhibition, its role in the prognosis of solid tumours has not been conclusively determined. Several studies strengths and limitations of this study ► This review included large sample size to reveal the relationship between the expression of liver kinase B1 (LKB1) and solid tumours. ► Subgroup analyses and sensitivity analyses were performed to confirm the findings. ► The cut-off value of LKB1 among the included studies were inconsistent.
Open access suggest that decreased LKB1 expression indicates poor prognosis. In fact, meta-analysis showed that decreased LKB1 expression in patients with solid tumours may be related to poor prognosis and serve as a predictor of clinicopathological prognostic factors. 11 However, other studies have not reproduced these findings, and some have even suggested that decreased LKB1 may correlate with favourable survival.
Therefore, we systematically reviewed and meta-analysed the relevant literature to understand the current evidence about a relationship between LKB1 expression and prognosis in patients with solid tumours.
MAtErIAls AnD MEthODs literature search strategy
The following databases were searched from database establishment to 15 June 2018 to identify studies of LKB1 expression and survival in solid tumours: PubMed, Embase, Web of Science, Cochrane Database, the Chinese National Knowledge Infrastructure and Wang Fang. Searches were carried out using terms such as LKB1, STK11, liver kinase B1, prognosis, prognostic, survival and overall survival. For example, we searched PubMed using the following strategy: (LKB1(tw) OR STK11(tw) OR 'liver kinase B1'(tw) OR 'serine-threonine kinase 11'(tw)) AND ('prognosis' (MeSH terms) OR prognoses(tw) OR prognostic(tw) OR 'prognostic factor'(tw) OR 'prognostic factors'(tw) OR factor(tw) OR factors(tw) OR outcome(tw) OR survival(tw) OR metastases(tw) OR metastasis(tw) OR migration(tw) OR transplantation(tw) OR transfer(tw) OR shift(tw) OR divert(tw) OR recurrence(tw) OR relapse(tw) OR reappear(tw) OR recur(tw) OR recidivation(tw) OR invasion(tw)). study inclusion and exclusion criteria Studies were considered eligible if they met the following criteria: (1) LKB1 expression in cancer tissue (obtained via surgery or biopsy) was measured by immunohistochemistry or western blot analysis; (2) the association was studied between LKB1 expression and clinicopathological characteristics, overall survival (OS), disease-free survival (DFS) or recurrence-free survival (RFS) of patients with solid tumours; (3) sufficient data were published for calculating an OR or HR and 95% CI and (4) the study was published as a full-text article in English or Chinese. If we retrieved multiple studies conducted by the same research group and involving overlapping patient populations, only the most recent or most complete study was included in the meta-analysis. Articles were excluded if they (1) were duplicate publications; (2) were case reports, reviews, letters or animal studies or (3) did not report survival outcomes. study quality assessment Two reviewers independently assessed the quality of included studies using the standard Newcastle-Ottawa Scale (NOS) from 0 to 9. NOS scores of 9-7 were defined as high quality, 6-4 as intermediate quality and 3-1 as low quality.
Data extraction
Two researchers (YHR and FJZ) independently screened all titles and abstracts identified in the initial search. Articles remaining after this screen were read in full and assessed for eligibility. The following types of data were extracted: (1) name of first author, publication year, country, type of cancer and number of patients; (2) patient's age, gender, follow-up time, type of LKB1 assay, intracellular location where LKB1 staining was examined, LKB1 cut-off value for classifying expression as high or low, survival data (OS, DFS, RFS), statistical method used to analyse survival data; (3) tumour differentiation, tumour size, lymph node metastasis and tumour stage. All data were cross-checked by two researchers, and disagreements were resolved by a third reviewer (XMY). If study information was incomplete or unclear, we contacted the corresponding author in an attempt to collect accurate information.
statistical analysis
Correlation between LKB1 expression and OS of patients with solid tumours was evaluated in terms of HR and 95% CI. If a study showed Kaplan-Meier survival curves but not HRs with 95% CI, data were extracted from survival curves using Engauge Digitizer 4.1 and the Tierney's table. Correlation between LKB1 expression and clinicopathological characteristics of patients with solid tumours was evaluated in terms of OR and 95% CI.
HRs and ORs were meta-analysed using the random-effects model in R software. P values were two-sided and values <0.05 were considered to be statistically significant.
I² was used to assess statistical heterogeneity. If I² was >50%, heterogeneity was considered to exist among all included studies, and we conducted a subgroup analysis to investigate its possible source. If I² was <50%, heterogeneity among all included studies was regarded as insignificant, and data were directly pooled.
To assess the stability of our meta-analysis results, we conducted a sensitivity analysis to test the influences of individual studies on the pooled HR or p value for the remaining studies. Potential for publication bias was assessed by examining funnel plots, Begg's test and Egger's test of survival data. rEsults A total of 4858 potentially relevant studies were identified in literature searches, of which 3374 were excluded as duplicate publications. After screening titles and abstracts, 50 studies were read in full, leading to 25 that were included in the meta-analysis ( figure 1 ). Data from all 25 studies were meta-analysed to examine the potential correlation of LKB1 expression with clinicopathological characteristics. Data from 24 studies were meta-analysed to examine the potential correlation Open access between LKB1 expression and OS. Data from five studies were used to analyse the potential correlation between LKB1 expression and DFS. Four studies reported the association of LKB1 expression with RFS.
Description of studies
The 25 studies in the systematic review involved 6012 patients from six countries: China, the USA, France, the UK, Canada and Egypt. Data on OS were reported in 24 studies, data on RFS in 5 studies and data on DFS in 4 studies. Patients covered a range of cancers, including cancers of the lung, breast, prostate or pancreas; gastric cancer; hepatocellular carcinoma; oesophagus squamous cancer; colorectal cancer; glioma and laryngeal squamous cell carcinoma. Tables 1-2 summarise the characteristics of the included studies. Online supplementary table 1 lists clinicopathological characteristics and LKB1 expression. Eight studies had a NOS score of 8; 11 studies, 7; 6 studies, 6 and 3 studies, 5 (online supplementary table 2  and online supplementary table 3) .
Of the 25 studies, 16 reported HRs from multivariate analysis, which we used directly. For the nine remaining studies, we estimated HRs for OS, DFS and RFS from survival curves and Tierney's table.
Association between lKb1 expression and Os Given heterogeneity among the studies (I²=74.0%, p<0.001), a random-effects model was used to meta-analyse the data. The pooled HR describing OS for patients with low LKB1 expression relative to OS for patients with high expression is shown in figure 2 . Decreased LKB1 expression was significantly associated with OS: low expression was associated with significantly higher risk of poor survival (HR=1.63, 95% CI 1.35 to 1.97, p<0.01).
To assess the predictive role of decreased LKB1, subgroup analysis was performed after stratifying the results based on multivariate analysis, type of LKB1 assay, country, cancer type and intracellular location of LKB1 staining that was examined. Subgroup analysis based on multivariate analysis showed that decreased LKB1 expression was related to poor OS in Details of the subgroup analysis are listed in table 3. The results of the sensitivity analysis showed that the exclusion of each single study did not alter the results significantly (figure 3). These results suggest that our meta-analysis gave credible results.
Association of lKb1 expression with DFs and rFs
Studies showed significant heterogeneity, so data were meta-analysed using a random-effects model. Low LKB1 expression did not show a significant association with RFS based on univariate analysis (HR=1.44, 95% CI 0.65 to 3.17, p=0.37) or multivariate analysis (HR=1.02, 95% CI 0.42 to 2.47, p=0.97). Similarly, no significant correlation was observed between LKB1 expression and DFS based on univariate analysis and random-effects meta-analysis (HR=1.49, 95% CI 0.73 to 3.01, p=0.27) (table 4).
Association between lKb1 expression and clinicopathological characteristics Meta-analysis of the relationship between LKB1 expression and clinicopathological characteristics (table 5) failed to show a significant association of decreased LKB1 expression with age (OR=0.78, 95% CI 0.57 to 1.05, p=0.10) or sex (OR=0.97, 95% CI 0.78 to 1.19, p=0.76). Open access Figure 2 Forest plot of the association between decrease liver kinase B1 expression and overall survival. IHC, immunohistochemistry; LKB1, liver kinase B1; NOS, Newcastle-Ottawa Scale; OS, overall survival; RFS, relapse-free survival.
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Results are shown as individual and pooled OR with 95% CIs.
Publication bias
Funnel plots of OS appeared asymmetric (figure 4), suggesting the possibility of publication bias among the included studies. However, findings with Begg's test (p=0.5402) and Egger's test (p=0.2414) implied no publication bias.
DIsCussIOn
This meta-analysis suggests that among patients with many kinds of solid tumours, low LKB1 expression is associated with worse OS, whereas LKB1 expression does not appear to significantly influence DFS or RFS. This suggests that low LKB1 expression may be a predictor of unfavourable prognosis. In fact, the available evidence suggests an association of low LKB1 expression with worse tumour differentiation, deeper invasion, more advanced clinical stages and earlier metastasis to lymph nodes and other organs. These findings are consistent with previous conclusions, 11 and they were confirmed in our data set using sensitivity analysis.
Some potentially interesting findings emerged from subgroup analyses conducted after stratifying the data according to various criteria. Our meta-analysis linked low LKB1 expression with poor prognosis in Asians but not in non-Asians, which may reflect genetic and environmental differences. While low LKB1 expression was associated with worse prognosis in patients with certain types of cancer (lung, gastric, pancreatic, breast), this was not the case in patients with hepatocellular carcinoma. This difference may relate to different comorbidities associated with the types of cancer. Lung cancer, stomach cancer, breast cancer and pancreatic cancer have high incidence rates around the world, and more studies have been done. The association between low expression of LKB1 and poor prognosis was observed when low expression was based on cytoplasmic staining, but not when it was based on nuclear staining. The reason may be that the regulation of mTORC1 by LKB1 and AMPK occurs on the exterior of RAB7/LAMP1-positive lysosomal membranes. 37 In this regulation, LKB1 phosphorylates and activates cell energy-sensing AMPK, which in turn negatively affects TORC1, which is important for controlling energy metabolism, cell survival and cell growth under conditions of metabolic stress, such as nutrient deficiency. Further studies are needed to elucidate the mechanism of action of LKB1.
Our meta-analysis suggests that at least in many types of solid tumours, LKB1 acts as a tumour suppressor. This is consistent with several studies in the literature. For example, a decrease in LKB1 expression as a result of HBx-mediated p53 inactivation may be responsible for colony formation and invasiveness in hepatocellular carcinoma. 29 LKB1 deficiency in some tumours may be associated with upregulation of glutamate dehydrogenase 1, which activates CamKK2 and its downstream effector AMPK to increase metastatic potential. 38 LKB1 loss may drive ovarian serous tumourigenesis by disrupting apicalbasal polarity in the presence of mutated p53 in fallopian tube cells. 39 On the one hand, several studies have suggested an oncogenic role for LKB1 and AMPK under certain conditions, 40 such as when class III phosphatidylinositol-3-OH kinase is inactivated. 41 Further work is needed to clarify under what conditions LKB1 acts as a tumourigenic or tumour-suppressing molecule. 
Open access
The results of our meta-analysis should be interpreted with caution given several limitations. First, we had to assess OS, DFS and/or RFS from Kaplan-Meier survival curves in several studies, such that HRs and 95% CIs were estimated indirectly. Second, studies showed substantial heterogeneity for outcomes, although we did attempt to minimise the effects of such heterogeneity by using a random-effects meta-analysis model, performing subgroup analyses and checking results through sensitivity analysis. Third, there is no consensus on LKB1 cut-off values for defining expression as low or high, which may influence conclusions about correlations and their clinical significance. Fourth, the funnel plots suggest the potential for publication bias. This may reflect the generally observed bias towards publication of positive findings. Fifth, our meta-analysis did not account for numerous other factors that may also affect prognosis, such as comorbidities and treatment history. In most cases, this information was not reported in the included studies.
Our results justify the design of rigorous in vitro and animal studies designed to explore how LKB1 influences the prognosis of various types of solid cancers. Ultimately, this work should be extended through human studies, preferentially randomised controlled trials.
COnClusIOns
The available evidence links low LKB1 expression with poor prognosis in patients with various types of solid tumours. This suggests that LKB1 may be a biomarker for various cancers. These findings should be verified and extended in human studies, and the mechanisms underlying the association of LKB1 expression and prognosis should be explored.
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